Fennec Pharmaceuticals Inc. Common Stock (FENC)

About FENC

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tamp…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

35

Website

fennecpharma.com/

Fundamentals

1-day range

$11.6$12.51

Market cap

$334.56M

P/E (trailing)

—

P/E (forward)

12.89

EPS (trailing)

$-0.28

Dividend yield

—

Beta

1.21

Avg. volume

226.2K

Forecasts

6 analyst ratings

Fennec Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• FENC

  Fennec Pharmaceuticals Inc. Common Stock

  $12.19

  ▲ 3.57%
  Market cap $334.56MP/E —
  $5.65$13.25
• PALI

  Palisade Bio Inc. Common Stock

  $2.01

  ▼ 4.74%
  Market cap $336.74MP/E 3.25
  $0.53$2.86
• AGEN

  Agenus Inc. Common Stock

  $7.67

  ▼ 1.79%
  Market cap $349.96MP/E 4.88
  $2.71$8.85
• IPSC

  Century Therapeutics Inc. Common Stock

  $2.03

  ▼ 9.19%
  Market cap $357.10MP/E —
  $0.435$3.04
• NMRA

  Neumora Therapeutics Inc. Common Stock

  $1.38

  ▼ 6.76%
  Market cap $303.87MP/E —
  $0.83015$3.65
• SABS

  SAB Biotherapeutics Inc. Common Stock

  $3.79

  ▼ 3.56%
  Market cap $289.80MP/E 26.94
  $1.85$5.15
• XFOR

  X4 Pharmaceuticals Inc. Common Stock

  $4.05

  ▼ 4.26%
  Market cap $385.77MP/E 2.95
  $2.8$4.83

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• B. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $18
  benzinga · 8/12/2026
• B. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $18
  Benzinga · 8/12/2026
• Wedbush Maintains Outperform on Fennec Pharmaceuticals, Raises Price Target to $16
  Benzinga · 8/12/2026
• Fennec: The Turnaround Is Real, But The Stock Prices In Perfection (Downgrade)
  SeekingAlpha · 8/12/2026
• Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/11/2026
• Fennec Pharmaceuticals Q2 EPS $0.05 Beats $0.02 Estimate, Sales $17.874M Beat $16.095M Estimate
  Benzinga · 8/11/2026

• Andrade Robert · August 28, 2026 · Option Exercise

  21.9K @ $5.1
• Andrade Robert · August 27, 2026 · Sale

  75.0K @ $11.78
• Raykov Rosty · August 3, 2026 · Sale

  10.0K @ $9.58
• Cioffi Christiana Marie · July 31, 2026 · Grant

  156
• Sayad Pierre Sargis · July 31, 2026 · Grant

  168
• Evans Terry L · July 31, 2026 · Grant

  168
• Hackman Jeffrey S. · July 31, 2026 · Grant

  1.2K
• Raykov Rosty · July 31, 2026 · Grant

  2.8K
• Andrade Robert · July 31, 2026 · Grant

  1.7K
• Raykov Rosty · July 1, 2026 · Option Exercise

  15.6K @ $2.45
• Raykov Rosty · July 1, 2026 · Sale

  9.6K @ $10.41
• Raykov Rosty · July 1, 2026 · Grant

  2.8K
• Cioffi Christiana Marie · June 30, 2026 · Grant

  156
• Sayad Pierre Sargis · June 30, 2026 · Grant

  168
• Evans Terry L · June 30, 2026 · Grant

  168

Institutional Ownership

March 31, 2026

Total shares held

16.00M

Total value held

$97.94M

Institutional holders

88